New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

As CIDP moves toward targeted therapies and patient-friendly regimens, the market is primed for disruption—offering a fresh ...

A new trial finds that intravenous immunoglobulin stabilises kidney function and slows damage in patients with chronic ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

The National Association of Experts in the Field of Primary Immunodeficiencies shared the results of a study evaluating the effectiveness of subcutaneous immunoglobulin administration in patients with ...

Results from the PATH study indicate that subcutaneous immunoglobulin ... CIDP remain dependent on life-long treatment with intravenous immunoglobulin (IVIg), which is not only time consuming ...

HyQvia (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion ... therapy after stabilization with intravenous immunoglobulin (IVIG) to prevent ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin ... solution for subcutaneous infusion) for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion ... therapy after stabilization with intravenous immunoglobulin (IVIG) to prevent relapse of ...

approval of intravenous immunoglobulin (IVIg), which became the standard therapy for immunoglobulin G (IgG) replacement. The approval of subcutaneous immunoglobulin (SCIg) in 2006 further ...